Discovery of a peroxisome proliferator activated receptor γ (PPARγ) modulator with balanced PPARα activity for the treatment of type 2 diabetes and dyslipidemia

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4443-4453

  Liu, Weiguo ^a   Liu, Kun ^a   Wood, Harold B ^a   McCann, Margaret E ^a   Doebber, Thomas W ^a   Chang, Ching H ^a   Akiyama, Taro E ^a   Einstein, Monica ^a   Berger, Joel P ^a   Meinke, Peter T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 [[3 (4 CHLOROBENZOYL) 2 METHYL 6 (TRIFLUOROMETHOXY) 1H INDOL 1 YL]METHYL]PHENOXY]BUTANOIC ACID; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; ROSIGLITAZONE; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DYSLIPIDEMIA; FEMALE; FLUID RETENTION; HEART HYPERTROPHY; HEART WEIGHT; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; SYRIAN HAMSTER;

ANIMALS; BLOOD GLUCOSE; BUTYRIC ACID; CELL LINE; CHOLESTEROL; CRICETINAE; DIABETES MELLITUS, TYPE 2; DOGS; DRUG DISCOVERY; DYSLIPIDEMIAS; FEMALE; HUMANS; INDOLES; MALE; MICE; PPAR GAMMA; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67650739081     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900367w     Document Type: Article

References (48)

1. (a) Kopelman, P. G.; Hitman, G. A. Diabetes, exploding type II. Lancet 1998, 352 (Suppl. 4), SIV5.
2. (b) Amos, A. F.; McCarthy, D. J.; Zimmet, P. The rising global burden of diabetes and its complications: estimates and projections by 2010. Diabet. Med. 1997, 14 (Suppl. 5), S5-S85.
3. Haffner, S. M.; Lehto, S.; Ronnemaa, T.; Pyorala, K.; Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with or without prior myocardial infarction. N. Engl. J. Med. 1998, 339, 229-234.
4. UKPDS.. UK prospective diabetes study 33: intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes. Lancet 1998, 352, 837-853.
5. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. The PPARs: from orphan receptor to drug discovery. J. Med. Chem. 2000, 43, 527-550.
6. Kersten, S.; Desvergne, B.; Wahli, W. Roles of PPARs in health and disease. Nature 2000, 405, 421-424.
7. Nuclear Receptors Nomenclature Committee, 1999. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999, 97, 161-163.
8. (a) Staels, B.; Dallongeville, J.; Auwerx, J.; Schoonjans, K.; Leitersdorf, E.; Fruchart, J. C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98, 2088-2093.
9. (b) Schoonjans, K.; Staels, B.; Auwerx, J. Role of the peroxisome proliferators-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 1996, 37, 907-925.
10. (a) Steiner, G. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357, 905-910.
11. (b) Rubins, H. B.; Robins, S. J. Conclutions from the VA-HIT study. Am. J. Cardiol. 2000, 86, 543-544.
12. (c) Rubins, H. B.; Robins, S. J.; Collins, D.; Fye, C. L.; Anderson, J. W.; Elam, M. B.; Faas, F. H.; Linares, E.; Schaefer, E. J.; Schectman, G; Wilt, T. J.; Wittes, J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. 1999, 341, 410-418.
13. Berger, J.; Bailey, P.; Biswas, C.; Cullinan, C. A.; Doebber, T. W.; Hayes, N. S.; Saperstein, R.; Smith, R. G.; Leibowitz, M. D. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlates with antidiabetic actions in db/db mice. Endocrinology 1996, 137, 4189-4195.
14. Oakes, N. D.; Kennedy, C. J.; Jenkins, A. B.; Laybutt, D. R.; Chisholm, D. J.; Kraegen, E. W. A new antidiabtic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994, 43, 1203-1210.
15. Henke, B. R. Peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes. J. Med. Chem. 2004, 47, 4118-4127.
16. (a) Lohray, B. B.; Lohray, V. B.; Bajji, A. C.; Kalchar, S.; Poondra, R. R.; Padakanti, S.; Chakrabarti, R.; Vikramadithyan, R. K.; Misra, P.; Juluri, S.; Mamidi, N. V. S. R.; Rajagopalan, R. (-)3-[4-[2-Phenoxazin-10-yl)ethoxy] phenyl]-2-ethoxypropanoic Acid [(-)DRF2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J. Med. Chem. 2001, 44, 2675-2678.
17. (b) Brooks, D. A.; Etgen, G. J.; Rito, C. J.; Shuker, A. J.; Dominianni, S. J.; Warshawsky, A. W.; Ardecky, R.; Paterniti, J. R.; Tyhonas, J.; Broderick, C. L.; Oldham, B. A.; Montrose-Rafizadeh, C.; Winneroski, L. L.; Faul, M. M.; McCarthy, J. R. Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol- 4-yl)ethoxy]phenoxy}propionic acids: a new class of dual PPARα/γ agonists. J. Med. Chem. 2001, 44, 2061-2064.
18. (c) Sauerberg, P.; Pettersson, I.; Jeppesen, L.; Bury, P. S.; Morgensen, J. P.; Wassermann, K.; Brand, C. L.; Sturis, J.; Woldike, H. F.; Fleckner, J.; Andersen, A. T.; Mortensen, S. B.; Svensson, I. A.; Rasmussen, H. B.; Lehmann, S. V.; Polivka, Z.; Sindelar, K.; Panajotova, V.; Ynddal, L.; Wulff, E. M. Novel tricyclic-α-alkoxyphenylpropionic acids: dual PPARα/γ agonists with hypolipidemic and antidiabetic activity. J. Med. Chem. 2002, 45, 789-804.
19. (d) Cheng, P. T.; Chandrasena, G.; Chen, S. BMS-298585 is a novel, uniquely balanced dual activator of peroxisome proliferator-activated receptors (PPAR) alpha and gamma, with an excellent ADME profile. Diabetes 2002, 51 (Suppl. 2), A94.
20. Nesto, R. W.; Bell, D.; Bonow, R. O.; Fonseca, V.; Grundy, S. M.; Horton, E. S.; Winter, M. L.; Porte, D.; Semenkovich, C. F.; Smith, S.; Young, L. H.; Kahn, R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004, 27, 256-263.
21. Kahn, S. E.; Zinman, B.; Lachin, J. M.; Haffner, S. M.; Herman, W. H.; Holman, R. R.; Kravitz, B. G.; Yu, D.; Heise, M. A.; Aftring, R. P.; Viberti, G. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care 2008, 31, 845-851.
22. Burgermeister, E.; Schnoebelen, A.; Flament, A.; Benz, J.; Stihle, M.; Gsell, B.; Rufer, A.; Kuhn, B.; Marki, H. P. A novel partial agonist of peroxisome proliferator-activated receptor-(PPAR) recruits PPAR-coactivator-1, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol. Endocrinol. 2006, 20, 809-830.
23. Berger, J. P.; Petro, A. E.; McNaul, K. L.; Kelly, L. J.; Zhang, B. B.; Richards, K.; Elbrecht, A.; Johnson, B. A.; Zhou, G.; Doebber, T. W.; Biswas, C.; Parikh, M.; Sharma, N.; Tanen, M. R.; Thompson, G. M.; Ventre, J.; Adams, A. D.; Mosley, R.; Surwit, R. S.; Moller, D. E. Distinct properties and advantages of a novel peroxisome proliferator-activated protein-selective modulator. Mol. Endocrinol. 2003, 17, 662-676.
24. Elbrecht, A.; Chen, Y.; Adams, A; Berger, J. P.; Griffin, P.; Klatt, T.; Zhang, B. B.; Menke, J.; Zhou, G.; Smith, R. G.; Moller, D. E. L-764406 is a partial agonist of human peroxisome proliferator-activated receptor-fx1. The role of CYS313 in ligand binding. J. Biol. Chem. 1999, 274, 7913-7922.
25. Shi, G. Q.; Dropinski, J. F.; Zhang, Y.; Santini, C.; Sahoo, S. P.; Berger, J. P.; MacNaul, K. L.; Zhou, G.; Agrawal, A.; Alvaro, R.; Cai, T.; Hernandez, M.; Wright, S. D.; Moller, D. E.; Heck, J. V.; Meinke, P. T. Novel 2-3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARα agonists with potent hypolipidemic activity. J. Med. Chem. 2005, 48, 5589-5599.
26. Koyama, H.; Miller, D. J.; Boueres, J. K.; Desai, R. C.; Jones, A. B.; Berger, J. P.; MacNaul, K. L.; Kelly, L. J.; Doebber, T. W.; Wu, M. S.; Zhou, G.; Wang, P. R.; Ippolito, M. C.; Chao, Y. S.; Agrawal, A. K.; Franklin, R.; Heck, J. V.; Wright, S. D.; Moller, D. E.; Sahoo, S. P. (2R)-2- Ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents. J. Med. Chem. 2004, 47, 3255-3263.
27. (a) Acton, J. J.; Black, R. M.; Jones, A. B.; Moller, D. E.; Colwell, L.; Doebber, T. W.; MacNaul, K. L.; Berger, J.; Wood, H. B. Benzoyl 2-methyl indoles as selective PPARγ modulators. Bioorg. Med. Chem. Lett. 2005, 15, 357-362.
28. (b) Liu, K.; Black, R. M.; Acton, J. A.; Mosley, R.; Debenham, S.; Abola, R.; Yang, M; Tschirret-Guth, R.; Colwell, L.; Liu, C.; Wu, M.; Wang, C. F.; MacNaul, K. L.; McCann, M. E.; Moller, D. E.; Berger, J. P.; Meinke, P. T.; Jones, A. B.; Wood, H. B. Selective PPARγ modulators with improved pharmacological profiles. Bioorg. Med. Chem. Lett. 2005, 15, 2437-2440.
29. Faiola, B.; Falls, J. G.; Peterson, R. A.; Bordelon, N. R.; Brodie, T. A.; Cummings, C. A.; Romach, E. H.; Millar, R. T. PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742. Toxicol. Sci. 2008, 105, 384-394.
30. (a) Malgres, P. E.; Mumphrey, G. R.; Marcoux, J-.F.; Hillier, M.; Zhao, D.; Krska, S.; Grabowski, E. J. J. Practical, highly convergent, asymmetric synthesis of a selecive PPARγ modulator. Org. Process Res. Dev., in press.
31. (b) Acton, J. J.; Akiyama, T. E.; Chang, C. H.; Colwell, L.; Debenham, S.; Doebber, T.; Einstein, M.; Liu, K.; McCann, M. E.; Moller, D. E.; Muise, E. S.; Tan, Y.; Thompson, J. R.; Wong, K. K.; Wu, M.; Xu, L.; Meinke, P. T.; Berger, J. P.; Wood, H. B. Discovery of MK-0533: a novel SPPARgM for the treatment of T2MD with a reduced potential to increase plasma volume and extracellular fluid. Manuscript in preparation.
32. For the binding assay procedure, see the following: Adams, A. D.; Yuen, W.; Hu, Z.; Santini, C.; Jones, A. B.; MacNaul, K. L.; Berger, J. P.; Doebber, T. W.; Moller, D. E. Amphipathic 3-phenyl-7-propylbenzisoxazoles; human PPARγ, δ and α agonists. Bioorg. Med. Chem. Lett. 2003, 13, 931-936.
33. Berger, J. B.; Bailey, P.; Biswas, C.; Cillinana, C. A.; Doebber, T. W.; Hayes, N. S.; Saperstein, R.; Smith, R. G.; Liebowitz, M. D. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996, 137, 4189-4195.
34. Bergeron, R; Yao, J.; Woods, J. W.; Zycband, E. I.; Liu, C.; Li, Z.; Adams, A.; Berger, J. P.; Zhang, B. B.; Moller, D. E.; Doebber, T. W. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: a comparison with PPAR gamma agonism. Endocrinology 2006, 147, 4252-4262.
35. Tsunoda, M.; Kobayashi, N.; Ide, T.; Utsumi, M.; Nagasawa, M.; Murakami, K. A novel PPARα agonist ameliorates insulin resistance in dogs fed a high-fat diet. Am. J. Physiol.: Endocrinol. Metab. 2008, 294, E833-E840.
36. Malinowski, J. M.; Bolesta, S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin. Ther. 2000, 22 (10), 1151-1168.
37. Davidson, M. H.; Jones, P. H. Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. Clin. Drug Invest. 2008, 28 (10), 615-623.
38. Debenham, S. D.; Chan, A.; Lau, F. W.; Liu, W.; Wood, H. B.; Lemme, K.; Colwell, L.; Habulihaz, B.; Akiyama, T. E.; Einstein, M.; Doebber, T. W.; Sharma, N.; Wang, C. F.; Wu, M.; Berger, J. P.; Meinke, P. T. Highly functionalized 7-azaindoles as selective PPARγ modulators. Bioorg. Med. Chem. Lett. 2008, 18, 4798-4801.
39. Willson, T. M.; Cobb, J. E.; Cowan, D. J.; Wiethe, R. W.; Correa, I. D.; Prakash, S. R.; Beck, K. D.; Moore, L. B.; Kliewer, S. A.; Lehmann, J. M. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the anti-hyperglycemic activity of thiazolidinediones. J. Med. Chem. 1996, 39 (3), 665-668.
40. Mu, J.; Woods, J.; Zhou; Roy, R. S.; Li, Z.; Zycband, E.; Feng, Y.; Zhu, L.; Li, C.; Howard, A. D.; Moller, D. E.; Thornberry, N. A.; Zhang, B. B. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006, 55 (6), 1695-1704.
41. Chang, C. H.; McNamara, L. A.; Wu, M. S.; Muise, E. S.; Tan, Y.; Wood, H. B.; Meinke, P. T.; Thompson, J. R.; Doebber, T. W.; Berger, J. P.; McCann, M. E. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARγM5 improves insulin sensitivity with diminished adverse cardiovascular effects. Eur. J. Pharmacol. 2008, 584, 192-201.
42. Spady, D. K.; Dietschy, J. M. Interaction of dietary cholesterol and triglycerides in the regulation of hepatic low density lipoprotein transport in the hamster. J. Clin. Invest. 1988, 81, 300-309.
43. Shunji, K; Takashi, I.; Hideki, Y.; Taro, H.; Fumiyoshi, M.; Hitoshi, H.; Masanobu, S.; Isao, T. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. J. Pharmacol. Sci. 2008, 108 (1), 40-48.
44. (a) Nedergaard, J.; Petrovic, N.; Lindgren, E. M.; Jacobsson, A.; Cannon, B. PPAR.γ in the control of brown adipocyte differentiation. Biochim. Biophy. Acta, Mol. Basis Dis. 2005, 1740 (2), 293-304.
45. (b) Buckingham, R E; Hanna, A. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?. Diabetes, obesity & metabolism 2008, 10 (4), 312-328.
46. Rosen, M. B.; Lee, J. S.; Ren, H.; Vallanat, B.; Liu, J.; Waalkes, M. P.; Abbott, B. D.; Lau, C.; Corton, J. C. Toxicogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPAR.α and CAR. Toxicol. Sci. 2008, 103 (1), 46-56.
47. Einstein, M.; Akiyama, T. E.; Castriota, G. A.; Wang, C. F.; McKeever, B.; Mosley, R. T.; Becker, J. W.; Moller, D. E.; Meinke, P. T.; Wood, H. B.; Berger, J. P. The differential interactions of peroxisome proliferator-activator receptor γ ligands with Tyr473 is a physical basis for their unique biological activities. Mol. Pharmacol. 2008, 73 (1), 62-74.
48. Belcher, E. H.; Harriss, E. B. Studies of plasma volume, red cell volume and total blood volume in young growing rats. J. Physiol. 1957, 139, 64-78.